Loading
companiesCompany
Kheiron Medical Technologies
Kheiron built Mia, an artificial intelligence system that reads screening mammograms so that one radiologist plus the software can match the quality of two human readers. RadNet's DeepHealth unit bought the London company in 2024.
Also called: KheironDeepHealth Kheiron
Overview
Kheiron Medical Technologies, founded in London in 2016, developed Mia (Mammography Intelligent Assessment), a deep-learning system for breast screening that can act as an independent second reader, a concurrent reader or a triage tool, aiming to deliver double-reading quality with a single human reader. Mia received CE marking in 2019, won the UK AI in Health and Care Award in 2020 and was deployed in what the company describes as the EU and UK's first prospective evaluation of a breast screening AI system. On 22 October 2024 DeepHealth, RadNet's wholly owned AI subsidiary, announced it had acquired Kheiron; financial terms were not disclosed. Kheiron's technology has since been folded into DeepHealth's SmartMammo breast screening product, and the former kheironmed.com domain redirects to DeepHealth.
Headquarters
London, GB
Scorecard
All companies#444of 1244 companies, score 7
- modalities +2
- regions +1
- registry trials +4
0 approved, 0 in phase 3, 0 earlier, 0 targets, 4 registry studies. Formula on the scorecards page.
Funding
All startupsAcquired
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Acquired by DeepHealth, a wholly owned subsidiary of RadNet, announced 22 October 2024; terms not disclosed. | 2024 | undisclosed | deephealth.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Acquired
Founded
2016
EstablishedAI mammography detection software (independent or second reader)
A London-built breast screening AI trialled across NHS sites as a second reader, now folded into RadNet's DeepHealth after a 2024 acquisition.
Notes
top- kheironmed.com returns a redirect to deephealth.com. Pre-acquisition venture rounds not sourced. Breast cancer subtypes are tagged collectively because screening AI is not subtype-specific.
Similar pages
- CompanyTherapixel
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- CompanyVara
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- CompanyVolpara Health
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- TreatmentTranspara
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- TreatmentProFound AI (iCAD)
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- JournalJournal of breast imaging
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CompanyiSono Health
Shares AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TrialTMIST (Tomosynthesis Mammographic Imaging Screening Trial)
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
cancers
fronts
technologies
drugs
EstablishedAI mammography detection software (independent or second reader)